- NLS Pharmaceutics ( NASDAQ: NLSP ) said Wednesday it received a notice from Nasdaq, indicating that it was not in compliance with the minimum bid price rule for continued listing.
- As the 180-day grace period to regain compliance expired, NLS ( NLSP ) received an additional notice from Nasdaq that the bid price issue provides a separate basis for delisting of shares.
- The firm informed the Nasdaq hearings panel about its plan to regain compliance and has been given an opportunity to provide a further update to the panel.
- The panel granted an extension through February 28 to regain compliance.
For further details see:
NLS Pharmaceutics not in compliance with Nasdaq's minimum bid price rule